VIVUS — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VIVUS is a commercial-stage biopharmaceutical company with a long history of developing and commercializing small molecule therapies. Its current focus appears to be on its obesity drug QSIVA®/QSYMIA® and the pancreatic enzyme product PANCREAZE®. The company has undergone significant restructuring, emerging in 2020 as a wholly-owned subsidiary of Icahn Enterprises L.P., and is now expanding its commercial footprint, particularly in Europe.

ObesityGastroenterologyMetabolic Disorders

Technology Platform

Clinical development and lifecycle management of small molecule drugs, including formulation optimization and supplemental indication development.

Opportunities

Significant opportunity exists in expanding the market share of QSIVA® in Europe against a backdrop of growing demand for obesity pharmacotherapies.

The stable, niche market for PANCREAZE® provides a consistent revenue base.

The company's structure under Icahn Enterprises allows for potential strategic acquisitions to bolster its portfolio.

Risk Factors

Intense competition in obesity care, particularly from newer drug classes with strong outcome data, poses a major commercial threat.

Heavy reliance on the success of QSIVA® in Europe creates concentration risk.

Strategic direction is dependent on the objectives of its parent holding company, Icahn Enterprises.

Competitive Landscape

In obesity, VIVUS competes directly with Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide), whose GLP-1-based therapies dominate the market. In EPI, PANCREAZE® competes with other pancreatic enzyme replacement therapies like Creon® (AbbVie) and Zenpep® (Nestlé Health Science). VIVUS's strategy relies on its oral formulation and established efficacy profile for QSIVA® in specific geographic markets.

More companies in Small Molecule Drugs →More companies in United States →